LT3190113T - Pirolopirimidino junginiai, naudotini kaip tlr7 agonistai - Google Patents
Pirolopirimidino junginiai, naudotini kaip tlr7 agonistaiInfo
- Publication number
- LT3190113T LT3190113T LTEP15831451.8T LT15831451T LT3190113T LT 3190113 T LT3190113 T LT 3190113T LT 15831451 T LT15831451 T LT 15831451T LT 3190113 T LT3190113 T LT 3190113T
- Authority
- LT
- Lithuania
- Prior art keywords
- pyrolopyrimidine
- compounds
- tlr7 agonists
- tlr7
- agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410405136.0A CN105367576A (zh) | 2014-08-15 | 2014-08-15 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| CN201510392499 | 2015-07-06 | ||
| PCT/CN2015/086909 WO2016023511A1 (zh) | 2014-08-15 | 2015-08-14 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3190113T true LT3190113T (lt) | 2021-08-25 |
Family
ID=55303885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP15831451.8T LT3190113T (lt) | 2014-08-15 | 2015-08-14 | Pirolopirimidino junginiai, naudotini kaip tlr7 agonistai |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9962388B2 (lt) |
| EP (1) | EP3190113B1 (lt) |
| JP (2) | JP6328341B2 (lt) |
| KR (2) | KR102215609B1 (lt) |
| CN (4) | CN110759916B (lt) |
| AU (3) | AU2015303558B2 (lt) |
| BR (1) | BR112017002811B1 (lt) |
| CA (1) | CA2958097C (lt) |
| CL (1) | CL2017000379A1 (lt) |
| DK (1) | DK3190113T3 (lt) |
| EA (1) | EA032824B1 (lt) |
| ES (1) | ES2875313T3 (lt) |
| HR (1) | HRP20210927T1 (lt) |
| HU (1) | HUE054672T2 (lt) |
| IL (2) | IL250586B (lt) |
| LT (1) | LT3190113T (lt) |
| MX (1) | MX386981B (lt) |
| MY (1) | MY190026A (lt) |
| PH (2) | PH12017500281B1 (lt) |
| PL (1) | PL3190113T3 (lt) |
| PT (1) | PT3190113T (lt) |
| SG (2) | SG11201701169XA (lt) |
| SI (1) | SI3190113T1 (lt) |
| UA (1) | UA117634C2 (lt) |
| WO (1) | WO2016023511A1 (lt) |
| ZA (1) | ZA201803736B (lt) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015282627B2 (en) | 2014-06-30 | 2020-04-02 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| AU2015303558B2 (en) * | 2014-08-15 | 2018-07-12 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pyrrolopyrimidine compounds used as TLR7 agonist |
| UA120450C2 (uk) | 2015-05-08 | 2019-12-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки і похідні сульфонімідоїлпуринону для лікування і профілактики вірусної інфекції |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| HUE052770T2 (hu) * | 2015-11-05 | 2021-05-28 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | 7-(Tiazol-5-il)pirrolopirimidin vegyület mint TLR7 agonista |
| CN107043380A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| CN107043378A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
| CN107043377A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途 |
| CN107043379A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
| DK3464336T3 (da) | 2016-06-01 | 2022-05-09 | Athira Pharma Inc | Forbindelser |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| KR102459155B1 (ko) | 2016-08-29 | 2022-10-28 | 에프. 호프만-라 로슈 아게 | 바이러스 감염의 치료 및 예방을 위한 7-치환된 설폰이미도일푸린온 화합물 |
| DK3510033T3 (da) | 2016-09-09 | 2022-02-28 | Novartis Ag | Forbindelser og sammensætninger som inhibitorer af endosomale toll-lignende receptorer |
| BR112019004560A2 (pt) | 2016-09-13 | 2019-07-02 | Hoffmann La Roche | tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv |
| US10662416B2 (en) | 2016-10-14 | 2020-05-26 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome |
| WO2018078149A1 (en) * | 2016-10-31 | 2018-05-03 | F. Hoffmann-La Roche Ag | Novel cyclicsulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection |
| EP3539963A4 (en) | 2016-11-11 | 2020-05-13 | Hepo Pharmaceutical Co., Ltd. | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE |
| MY192084A (en) * | 2016-11-28 | 2022-07-26 | Jiangsu Hengrui Medicine Co | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof |
| US11111249B2 (en) | 2017-05-18 | 2021-09-07 | Jiangsu Hengrui Medicine Co., Ltd. | Heteroaryl-pyrazole derivative, and preparation method therefor and medical application thereof |
| US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
| US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
| US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
| US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
| US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
| US20210253593A1 (en) | 2017-11-14 | 2021-08-19 | Bristol-Myers Squibb Company | Substituted indole compounds |
| MX2020006093A (es) | 2017-12-15 | 2020-08-24 | Bristol Myers Squibb Co | Compuestos de indol eter sustituidos. |
| PE20210129A1 (es) | 2017-12-18 | 2021-01-19 | Bristol Myers Squibb Co | Compuestos de 4-azaindol |
| CN111491930B (zh) | 2017-12-19 | 2023-09-26 | 百时美施贵宝公司 | 可用作tlr抑制剂的经取代的吲哚化合物 |
| BR112020011788A2 (pt) | 2017-12-19 | 2020-11-24 | Bristol-Myers Squibb Company | compostos 6-azaindóis |
| ES2922174T3 (es) | 2017-12-19 | 2022-09-09 | Bristol Myers Squibb Co | Compuestos de indol sustituidos con amida útiles como inhibidores de TLR |
| JP7291707B2 (ja) | 2017-12-20 | 2023-06-15 | ブリストル－マイヤーズ スクイブ カンパニー | アリールおよびヘテロアリール置換されたインドール化合物 |
| CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
| US11299501B2 (en) * | 2017-12-20 | 2022-04-12 | Bristol-Myers Squibb Company | Diazaindole compounds |
| KR102714788B1 (ko) | 2017-12-20 | 2024-10-08 | 브리스톨-마이어스 스큅 컴퍼니 | Tlr 억제제로서 유용한 아미노 인돌 화합물 |
| US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| EP3752505B1 (en) | 2018-02-12 | 2023-01-11 | F. Hoffmann-La Roche AG | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
| US10836769B2 (en) | 2018-02-26 | 2020-11-17 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| EP3816166A4 (en) * | 2018-05-25 | 2022-04-06 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Tlr7 agonist and pharmaceutical combination thereof for treating lung cancer |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| CN116098905A (zh) * | 2018-10-12 | 2023-05-12 | 正大天晴药业集团股份有限公司 | 用于治疗结直肠癌的tlr7激动剂及其药物组合 |
| EP3870589B1 (en) | 2018-10-24 | 2023-09-06 | Bristol-Myers Squibb Company | Substituted indole dimer compounds |
| KR102839382B1 (ko) | 2018-10-24 | 2025-07-25 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 인돌 및 인다졸 화합물 |
| EP4371987B9 (en) | 2018-10-31 | 2025-11-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| KR102658602B1 (ko) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물 |
| WO2020160711A1 (en) * | 2019-02-07 | 2020-08-13 | Beigene, Ltd. | Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist |
| JP7287708B2 (ja) | 2019-02-08 | 2023-06-06 | プロジェニア インコーポレイテッド | Ｔｏｌｌ－ｌｉｋｅ受容体７または８アゴニストとコレステロールの結合体およびその用途 |
| US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| CN113543851B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| EP3937944A1 (en) * | 2019-03-15 | 2022-01-19 | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd | Toll-like receptor agonists for use in the treatment of hepatitis b |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202103704A (zh) * | 2019-04-23 | 2021-02-01 | 大陸商正大天晴藥業集團股份有限公司 | 一種tlr7激動劑的固體藥物組成物 |
| EP3965888B1 (en) | 2019-05-09 | 2024-08-21 | Bristol-Myers Squibb Company | Substituted benzimidazolone compounds |
| WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| WO2021023105A1 (zh) | 2019-08-02 | 2021-02-11 | 百济神州有限公司 | 咪唑并[2,1-f][1,2,4]三嗪-4-胺衍生物作为tlr8激动剂 |
| EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| JP7749545B6 (ja) * | 2019-09-29 | 2025-11-14 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | Ｔｌｒ７作用薬を含む薬物の組み合わせ |
| CA3149557A1 (en) | 2019-09-30 | 2021-04-08 | Scott J. Balsitis | Hbv vaccines and methods treating hbv |
| WO2021067326A1 (en) | 2019-10-01 | 2021-04-08 | Bristol-Myers Squibb Company | Substituted bicyclic heteroaryl compounds |
| ES2965164T3 (es) | 2019-10-04 | 2024-04-11 | Bristol Myers Squibb Co | Compuestos de carbazol sustituidos |
| WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| US20230348468A1 (en) | 2020-01-27 | 2023-11-02 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| CN115210236A (zh) | 2020-01-27 | 2022-10-18 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
| EP4097106A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
| EP4097103A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
| KR20220132595A (ko) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 C3-치환된 1H-피라졸로[4,3-d]피리미딘 화합물 |
| EP4097101A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
| JP2023512208A (ja) | 2020-01-27 | 2023-03-24 | ブリストル－マイヤーズ スクイブ カンパニー | トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物 |
| EP4097105A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
| KR20220132591A (ko) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
| AU2021231160A1 (en) | 2020-03-02 | 2022-09-22 | Progeneer Inc. | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| KR20230035031A (ko) | 2020-06-05 | 2023-03-10 | 킨네이트 바이오파마 인크. | 섬유아세포 성장 인자 수용체 키나아제의 억제제 |
| WO2022031021A1 (ko) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신 |
| EP4194008A4 (en) | 2020-08-04 | 2025-01-08 | Progeneer Inc. | Kinetically acting adjuvant ensemble |
| JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途 |
| CN114805392A (zh) * | 2021-01-20 | 2022-07-29 | 上海维申医药有限公司 | 大环tlr7激动剂、其制备方法、药物组合物及其用途 |
| WO2022206752A1 (zh) * | 2021-03-29 | 2022-10-06 | 正大天晴药业集团股份有限公司 | Toll样受体7激动剂和抗PD-L1抗体的药物联合 |
| JP2024518558A (ja) | 2021-05-13 | 2024-05-01 | ギリアード サイエンシーズ， インコーポレイテッド | ＴＬＲ８調節化合物と抗ＨＢＶ ｓｉＲＮＡ治療薬との組合せ |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN114409654A (zh) * | 2021-12-30 | 2022-04-29 | 安徽普利药业有限公司 | 一种btk抑制剂的中间体合成方法 |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9020931D0 (en) * | 1990-09-26 | 1990-11-07 | Wellcome Found | Heterocyclic compounds |
| CA2230808C (en) | 1996-07-03 | 2006-08-15 | Japan Energy Corporation | A novel purine derivative |
| US6329381B1 (en) | 1997-11-28 | 2001-12-11 | Sumitomo Pharmaceuticals Company, Limited | Heterocyclic compounds |
| CN1845745B (zh) * | 2003-09-05 | 2011-11-02 | 安那迪斯药品股份有限公司 | Tlr7配体及其前药在制备用于治疗丙型肝炎病毒感染的药物中的用途 |
| ES2577514T3 (es) * | 2005-08-22 | 2016-07-15 | The Regents Of The University Of California | Antagonistas de TLR |
| PT2510946E (pt) * | 2007-02-07 | 2015-11-23 | Univ California | Conjugados de agonistas sintéticos de tlr e suas utilizações |
| PE20081887A1 (es) * | 2007-03-20 | 2009-01-16 | Dainippon Sumitomo Pharma Co | Nuevo compuesto de adenina |
| TWI434849B (zh) * | 2007-06-29 | 2014-04-21 | Gilead Sciences Inc | 類鐸（Ｔｏｌｌ－ｌｉｋｅ）受體７之調節劑 |
| ATE501136T1 (de) | 2007-08-03 | 2011-03-15 | Pfizer Ltd | Imidazopyridinone |
| SG172060A1 (en) | 2008-12-09 | 2011-07-28 | Gilead Sciences Inc | Modulators of toll-like receptors |
| EP2571882A1 (en) * | 2010-05-21 | 2013-03-27 | Gilead Sciences, Inc. | Heterocyclic flaviviridae virus inhibitors |
| DE102011008352A1 (de) * | 2011-01-12 | 2012-07-12 | Merck Patent Gmbh | 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate |
| WO2012106522A2 (en) * | 2011-02-04 | 2012-08-09 | Duquesne University Of The Holy Spirit | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
| EP2674170B1 (en) * | 2012-06-15 | 2014-11-19 | Invivogen | Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids |
| TR201807076T4 (tr) * | 2012-10-10 | 2018-06-21 | Janssen Sciences Ireland Uc | Viral enfeksiyonların ve diğer hastalıkların tedavisine yönelik pirolo[3,2-d]pirimidin derivatları. |
| PL2922549T3 (pl) * | 2012-11-20 | 2017-11-30 | Glaxosmithkline Llc | Nowe związki |
| JP6216386B2 (ja) * | 2012-11-20 | 2017-10-18 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 新規化合物 |
| AU2013348217B2 (en) * | 2012-11-20 | 2016-10-06 | Glaxosmithkline Llc | Novel compounds |
| WO2015124591A1 (en) | 2014-02-20 | 2015-08-27 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyrrolo[3,2] pyrimidine derivatives as inducers of human interferon |
| ES2908150T3 (es) | 2014-05-01 | 2022-04-27 | Novartis Ag | Compuestos y composiciones como agonistas del receptor de tipo Toll 7 |
| KR102139847B1 (ko) | 2014-05-01 | 2020-07-31 | 노파르티스 아게 | 톨-유사 수용체 7 효능제로서의 화합물 및 조성물 |
| AU2015303558B2 (en) * | 2014-08-15 | 2018-07-12 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pyrrolopyrimidine compounds used as TLR7 agonist |
| CN105732635A (zh) | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
-
2015
- 2015-08-14 AU AU2015303558A patent/AU2015303558B2/en active Active
- 2015-08-14 BR BR112017002811-5A patent/BR112017002811B1/pt active IP Right Grant
- 2015-08-14 CN CN201911022725.XA patent/CN110759916B/zh active Active
- 2015-08-14 SG SG11201701169XA patent/SG11201701169XA/en unknown
- 2015-08-14 KR KR1020177007194A patent/KR102215609B1/ko active Active
- 2015-08-14 SG SG10201809918RA patent/SG10201809918RA/en unknown
- 2015-08-14 PT PT158314518T patent/PT3190113T/pt unknown
- 2015-08-14 KR KR1020197024042A patent/KR20190098277A/ko not_active Ceased
- 2015-08-14 PL PL15831451T patent/PL3190113T3/pl unknown
- 2015-08-14 HU HUE15831451A patent/HUE054672T2/hu unknown
- 2015-08-14 US US15/503,977 patent/US9962388B2/en active Active
- 2015-08-14 EA EA201790389A patent/EA032824B1/ru unknown
- 2015-08-14 LT LTEP15831451.8T patent/LT3190113T/lt unknown
- 2015-08-14 SI SI201531613T patent/SI3190113T1/sl unknown
- 2015-08-14 HR HRP20210927TT patent/HRP20210927T1/hr unknown
- 2015-08-14 MY MYPI2017700489A patent/MY190026A/en unknown
- 2015-08-14 UA UAA201702350A patent/UA117634C2/uk unknown
- 2015-08-14 CN CN201911020774.XA patent/CN110938076B/zh active Active
- 2015-08-14 ES ES15831451T patent/ES2875313T3/es active Active
- 2015-08-14 CN CN202110224402.XA patent/CN112898308A/zh active Pending
- 2015-08-14 WO PCT/CN2015/086909 patent/WO2016023511A1/zh not_active Ceased
- 2015-08-14 CN CN201580041989.3A patent/CN106661034B/zh active Active
- 2015-08-14 DK DK15831451.8T patent/DK3190113T3/da active
- 2015-08-14 CA CA2958097A patent/CA2958097C/en active Active
- 2015-08-14 JP JP2017527961A patent/JP6328341B2/ja active Active
- 2015-08-14 EP EP15831451.8A patent/EP3190113B1/en active Active
- 2015-08-14 MX MX2017002028A patent/MX386981B/es unknown
-
2017
- 2017-02-14 IL IL250586A patent/IL250586B/en active IP Right Grant
- 2017-02-14 CL CL2017000379A patent/CL2017000379A1/es unknown
- 2017-02-15 PH PH12017500281A patent/PH12017500281B1/en unknown
-
2018
- 2018-04-17 US US15/955,523 patent/US10555949B2/en active Active
- 2018-04-17 JP JP2018079330A patent/JP6639551B2/ja active Active
- 2018-06-06 ZA ZA2018/03736A patent/ZA201803736B/en unknown
- 2018-10-01 AU AU2018236899A patent/AU2018236899B2/en active Active
-
2019
- 2019-10-22 AU AU2019253788A patent/AU2019253788C1/en active Active
-
2020
- 2020-07-16 PH PH12020551089A patent/PH12020551089A1/en unknown
- 2020-08-25 IL IL276908A patent/IL276908A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3190113T (lt) | Pirolopirimidino junginiai, naudotini kaip tlr7 agonistai | |
| IL250923A0 (en) | Novel compounds as rearranged during transfection (ret) inhibitors | |
| LT3223822T (lt) | Tulžies rūgšties dariniai, kaip fxr/tgr5 agonistai | |
| LT3197883T (lt) | Nauji junginiai | |
| LT3371190T (lt) | Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai | |
| DK3209656T3 (da) | Indolcarboxamidforbindelser, der er anvendelige som kinasehæmmere | |
| LT3134402T (lt) | 4-amino-imidazochinolino junginiai | |
| LT3105226T (lt) | Ciklopropilaminai, kaip lsd1 inhibitoriai | |
| HUE042964T2 (hu) | Szubsztituált dihidro-izokinolinon vegyületek | |
| DK3040326T3 (da) | Haloolefin-baseret sammensætning | |
| ZA201703007B (en) | Boronic acid derivatives | |
| FR3024363B1 (fr) | Composition thermogelifiable | |
| SG11201702625PA (en) | Boronic acid derivatives | |
| ZA201604527B (en) | Compounds for use as gpr120 agonists | |
| SG11201702620SA (en) | Boronic acid derivatives | |
| SG11201702623TA (en) | Boronic acid derivatives | |
| IL250038A0 (en) | 4,5 - dehydroisoxazole derivatives used as nampt inhibitors | |
| CL2016002165A1 (es) | Compuestos de aminocarbonilcarbamato | |
| HRP20190583T1 (hr) | Postupci za pripremu spoja diariltiohidantoina | |
| CL2017000639A1 (es) | Composición | |
| DK3191466T3 (da) | Azetidinyloxyphenylpyrrolidinforbindelser | |
| LT3253749T (lt) | Junginiai, pasižymintys priešnavikiniu aktyvumu | |
| DK3792251T3 (da) | Hidtil ukendte sulfonylaminobenzamidforbindelser som anthelmintika | |
| HUE039805T2 (hu) | Új szulfonilaminobenzamid vegyületek | |
| LT3233862T (lt) | Imidazopiridazino dariniai, kaip pi3kbeta slopikliai |